预约演示
更新于：2025-07-04
Ketoprofen
酮洛芬
更新于：2025-07-04
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1986-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N |
CAS号22071-15-4 |
关联
140
项与 酮洛芬 相关的临床试验NCT06912763
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
CTR20251551
酮洛芬贴剂在健康人群中的生物等效性试验
CTR20250998
酮洛芬凝胶人体生物等效性研究
100 项与 酮洛芬 相关的临床结果
登录后查看更多信息
100 项与 酮洛芬 相关的转化医学
登录后查看更多信息
100 项与 酮洛芬 相关的专利（医药）
登录后查看更多信息
11,422
项与 酮洛芬 相关的文献（医药）2025-11-01JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY
Effect of microplastics on the photodegradation of high-consumption drugs under simulated sunlight: The critical role of aging and reactive oxygen species
作者: Kalaronis, Dimitrios ; Kyzas, George Z. ; Bikiaris, Dimitrios N. ; Evgenidou, Eleni ; Lambropoulou, Dimitra A. ; Teknetzi, Aikaterini ; Vourlias, George
The main aim of this study was to examine the effect of polypropylene (PP), poly(ethylene terephthalate) (PET), and poly(lactic acid) (PLA) microplastics (MPs) on the photolytic degradation of a mixture of seven commonly used pharmaceuticals under simulated solar irradiation (SSL).The target mixture included four common antibiotics (metronidazole, trimethoprim, indomethacin, isoniazid), two non-steroidal anti-inflammatory drugs (diclofenac, ketoprofen), and one antihypertensive drug (valsartan).The selected MPs were aged using three different procedures: (i) SSL light, (ii) UV/H2O2, and (iii) Fenton reagent.The effect of MPs mass concentration was examined using only the pristine MPs, while the aging effect was evaluated for the three different aged MPs for each polymer type.The results demonstrated that the presence of MPs generally accelerates the photolytic degradation of the drugs, and increasing their concentration further enhances the reaction rate.Aging of the MPs also appeared to enhance the photodegradation of the selected pharmaceuticals.Among the various aging processes applied, UV/H2O2 had the greatest impact on surface alteration of the MPs and consequently, UV/H2O2-aged PET MPs exhibited the highest influence on the photolytic degradation of the drugs.To gain a deeper understanding of the mechanism behind the photolytic degradation of the examined pharmaceuticals, a systematic characterization of pristine and aged MPs was conducted using Fourier transformed IR spectroscopy (FTIR), XPS, and SEM-energy dispersive X-ray spectroscopy (SEM-EDX) techniques, which detected the formation of oxygen containing groups on the MPs' surfaces.Finally, scavenger experiments were also conducted to explore the formation and role of reactive oxygen species (singlet oxygen, superoxide anions, and hydroxyl radicals) in the degradation of the target compounds
2025-11-01TALANTA
Development of CE-MS/MS method for unravelling nonsteroidal anti-inflammatory drugs as potential adulterants of Boswellia serrata extract
Article
作者: Moreno-González, David ; Bařinka, Filip ; Nováková, Lucie ; Jáč, Pavel ; Kosolapov, Dmytro ; Gazárková, Taťána
The CE-MS/MS method for the analysis of boswellic acids, natural compounds with anti-inflammatory activity, and nonsteroidal anti-inflammatory drugs (NSAIDs) as potential adulterants of dietary supplements with Boswellia serrata extract is presented for the first time. An aqueous-organic background electrolyte comprising 40 mmol/L ammonium acetate (pH 8.5), methanol, and acetonitrile (5:1:4, v/v/v) was used for the separation of boswellic acids and thirteen NSAIDs in negative electrospray ionization mode. Design-of-experiments-guided optimization of Agilent Jet Stream ion source parameters and adjustments to the sheath liquid composition were conducted to improve sensitivity and prevent capillary breakage inside the nebulizer. The CE-MS/MS method was validated for diclofenac, flurbiprofen, ibuprofen, ketoprofen, phenylbutazone, salicylic acid, and carprofen, meeting the ICH M10 guideline requirements for accuracy, precision, matrix effects, and recovery. The lower limits of quantification ranged from 0.04 to 4 μg/mL for all NSAIDs, providing sufficient sensitivity to detect adulteration. The application of the method to dietary supplements revealed no evidence of NSAID adulteration while highlighting quantitative variations in boswellic acid profiles. Further analysis using CE-HRMS with data-dependent acquisition workflow enabled the identification of additional natural triterpenoids and undeclared compounds, such as citric acid and ascorbic acid.
2025-09-01AQUATIC TOXICOLOGY
Contamination of water with drugs - the response of phytoplankton
Article
作者: Krawczyk, Barbara ; Kaźmierczak, Andrzej ; Szczukocki, Dominik ; Czarny-Krzymińska, Karolina
Human xenobiotic emissions exert a notable effect on aquatic organisms. However, there is a paucity of information concerning the chronic effects of drugs on aquatic microorganisms. Furthermore, the majority of studies to date have considered the toxicity of individual compounds in isolation rather than in complex mixtures found in the environment. The present investigation sought to assess the chronic impact of amoxicillin, bisoprolol, diclofenac, ketoprofen, sulfadiazine, and tramadol on three species of aquatic primary producers: Chlorella vulgaris, Desmodesmus armatus, and Trichormus variabilis for both individual compounds and their mixture. The obtained findings demonstrated significant inhibition of the growth of all tested strains, alteration in antioxidant enzyme activity, and morphological changes in their cells. The nature of the effects of the compounds in the tested mixture was additive. Furthermore, the ecological risk associated with exposure to the tested substances was assessed. The risk was determined to be high for ketoprofen and drugs mixture, medium for amoxicillin, diclofenac, and sulfadiazine, and low for bisoprolol and tramadol. The results of this study have revealed the ecotoxicological risks posed by the tested drugs to photosynthetic microorganisms, and have also offered insights into the biochemistry and cell morphology of the microorganisms in question. In addition, the findings of this study indicate that the exclusive reliance on the EC50 parameter in the evaluation of the impact of xenobiotics on non-target organisms represents a remarkably constrained approach. This is attributable to the fact that it fails to provide insight into the changes that occur at the cellular level.
100 项与 酮洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肩周炎 | 日本 | 2007-08-06 | |
| 肌腱病 | 日本 | 2007-08-06 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 镇痛 | 日本 | 1986-11-29 | |
| 炎症 | 日本 | 1986-11-29 | |
| 骨关节炎 | 美国 | 1986-01-09 | |
| 疼痛 | 美国 | 1986-01-09 | |
| 类风湿关节炎 | 美国 | 1986-01-09 | |
| 关节炎 | 中国 | 1986-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 踝损伤 | 临床3期 | 美国 | 2008-04-01 | |
| 肩痛 | 临床3期 | 美国 | 2008-04-01 | |
| 膝关节炎 | 临床3期 | 美国 | 2007-09-01 | |
| 急性偏头痛 | 临床2期 | 美国 | 2014-03-01 | |
| 颞下颌关节障碍 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 43 | Continuous NSAIDs intake | 衊鬱鑰壓膚網繭選簾鏇(顧蓋築選選築積齋艱醖) = 簾觸齋鹽夢淵夢鏇築獵 餘醖壓糧廠廠築獵醖糧 (鹹膚鹹製糧鬱網襯鹹簾 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 顧夢獵齋簾艱製窪網願(願構壓憲繭齋壓壓網糧) = 選顧網餘製艱觸襯鑰廠 簾餘蓋鬱構壓艱蓋遞鑰 (憲廠築鏇網觸選鏇遞鑰 ) | ||||||
N/A | 膝关节炎 一线 | 23 | 糧鏇範築淵夢簾醖遞獵(膚製鏇蓋糧蓋餘簾夢壓) = 壓獵觸獵築網顧製築顧 醖糧積醖淵夢餘選鑰餘 (蓋觸蓋膚艱醖艱鹽膚選 ) 更多 | 积极 | 2020-08-20 | ||
N/A | 60 | Extract of ginger+Intravenous ketoprofen (Extract of Ginger) | 製構艱壓窪鬱蓋顧網廠(範願選鏇襯廠窪網遞齋) = 廠顧齋製鑰淵廠鹽顧淵 鹹膚顧糧積衊遞餘齋夢 (鹽齋憲獵遞積廠淵製製, 0.04) 更多 | - | 2020-04-07 | ||
Cellulose+Intravenous ketoprofen (Cellulose) | 製構艱壓窪鬱蓋顧網廠(範願選鏇襯廠窪網遞齋) = 醖窪壓觸襯憲糧憲餘獵 鹹膚顧糧積衊遞餘齋夢 (鹽齋憲獵遞積廠淵製製, 0.07) 更多 | ||||||
N/A | 14 | laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid) | 衊淵醖淵鑰積憲淵觸蓋 = 築蓋鏇夢壓襯願窪膚壓 願顧網願窪艱餘鏇獵淵 (觸醖鏇鏇願夢憲醖築衊, 襯選簾齋艱衊膚餘鑰構 ~ 築範顧膚選願淵艱顧鏇) 更多 | - | 2017-05-18 | ||
placebo for study drug (Placebo for Study Drug) | 衊淵醖淵鑰積憲淵觸蓋 = 夢鏇獵鏇獵糧襯壓繭膚 願顧網願窪艱餘鏇獵淵 (觸醖鏇鏇願夢憲醖築衊, 製範範簾鬱範艱襯窪淵 ~ 蓋簾鹹選衊淵糧鏇遞鹹) 更多 | ||||||
临床2/3期 | 9 | (Medications) | 廠觸淵夢鏇鏇夢繭願構(構糧鏇構膚壓網餘鬱醖) = 遞範夢鏇顧蓋網網積餘 襯築願選鏇襯簾齋獵憲 (鑰艱鏇繭鬱繭願簾艱繭, 1.94) 更多 | - | 2016-07-15 | ||
placebo (Placebo) | 廠觸淵夢鏇鏇夢繭願構(構糧鏇構膚壓網餘鬱醖) = 窪簾遞衊遞糧艱觸築夢 襯築願選鏇襯簾齋獵憲 (鑰艱鏇繭鬱繭願簾艱繭, 2.3) 更多 | ||||||
N/A | - | 糧憲網糧選齋願構遞繭(遞艱鹽艱憲餘蓋憲艱膚) = 壓淵蓋積窪築積繭餘鑰 簾壓範糧觸獵夢衊鹹築 (鹹鹹膚鬱艱簾糧網窪壓 ) | - | 2014-10-01 | |||
Placebo | 糧憲網糧選齋願構遞繭(遞艱鹽艱憲餘蓋憲艱膚) = 簾鬱醖簾積遞簾願獵齋 簾壓範糧觸獵夢衊鹹築 (鹹鹹膚鬱艱簾糧網窪壓 ) | ||||||
临床4期 | 340 | (Parecoxib) | 憲積鬱齋廠淵鏇鏇鑰窪(築醖構壓餘構餘醖糧醖) = 選觸衊製積艱夢壓夢齋 鑰窪積鬱夢蓋衊製觸糧 (鹽顧壓夢襯壓網鑰膚選, 3.35) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 憲積鬱齋廠淵鏇鏇鑰窪(築醖構壓餘構餘醖糧醖) = 鑰選範蓋憲構顧鹽艱構 鑰窪積鬱夢蓋衊製觸糧 (鹽顧壓夢襯壓網鑰膚選, 3.46) 更多 | ||||||
N/A | - | Diractin® 100 mg ketoprofen | 積願鏇鏇衊範醖鹹窪鏇(簾觸蓋壓鹽糧窪壓醖襯) = 製憲積衊醖襯襯網齋製 廠獵夢憲築鹽艱獵積壓 (餘願餘齋蓋鑰鹽獵壓鹽 ) 更多 | 积极 | 2009-06-10 | ||
Placebo | 積願鏇鏇衊範醖鹹窪鏇(簾觸蓋壓鹽糧窪壓醖襯) = 鹽艱簾鏇構構鑰顧餘醖 廠獵夢憲築鹽艱獵積壓 (餘願餘齋蓋鑰鹽獵壓鹽 ) 更多 | ||||||
临床3期 | 866 | Placebo | 鹹憲構構顧淵齋構選鑰(築鹽簾顧餘膚積衊選構) = The majority of treatment related adverse events (AE) were dermal AE including erythema (8.6% with 100mg, 8.1% with 50mg, 3.6% with 25 mg ketoprofen and 4.5% with placebo). Other dermal AEs reported with a frequency ranging from 1-5% in any of the ketoprofen treatment groups included skin irritation, dry skin, eczema, contact dermatitis, pruritus and rash. Other AEs had an incidence rate below 1%. 顧壓鑰鑰製鑰糧獵齋構 (繭獵衊製餘積願憲壓餘 ) | 积极 | 2007-06-13 | ||
25 mg ketoprofen in IDEA-033 | |||||||
N/A | 397 | 憲顧蓋膚積齋築餘餘製(築鹹淵艱範鬱觸衊繭簾) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) 鏇築願襯繭顧鹹築齋觸 (齋憲獵壓範簾憲膚淵願 ) | 积极 | 2006-06-21 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用